PLYMOUTH MEETING, PA — Harmony Biosciences Holdings (Nasdaq: HRMY) will present at two healthcare-focused investor conferences next week as the rare-disease drug developer engages with investors amid ongoing efforts to expand its neurological disease portfolio.
The company said members of its management team will participate in fireside chats at the Goldman Sachs 47th Annual Global Healthcare Conference and the Oppenheimer CNS & Neuro-Muscular Summit, both being held in Miami.
Harmony is scheduled to appear at the Goldman Sachs conference on June 9 at 8:40 a.m. Eastern time and at the Oppenheimer event on June 10 at 3:25 p.m. Eastern time.
Webcasts of both presentations will be available through the company’s investor relations website at https://ir.harmonybiosciences.com/.
Harmony Biosciences develops and commercializes therapies for patients with rare neurological disorders. The company, founded in 2017 and headquartered in Plymouth Meeting, markets treatments for conditions with limited therapeutic options and continues to invest in its pipeline of neurological disease programs.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.